RxDoctor Payments DataLook up a doctor →

Kashif Latif, MD

Endocrinology · Bartlett, TNNPI 1902913692

Payments from drug & device makers

$1,050,496in general payments, 2019–2025

Across 2,782 payments — averaging $377.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$272K
  • Novo Nordisk AS$169K
  • Sanofi-aventis U.S. LLC$139K
  • Mannkind Corporation$101K
  • Senseonics, Incorporated$91K
  • Eli Lilly$84K
  • plus $194K from 52 others
$124,623in research payments, 2019–2025

Across 18 payments — averaging $6923.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$79K
  • Sanofi US Services Inc.$46K
  • Mannkind Corporation$345

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)57$271,779
Novo Nordisk AS1,391$169,476
Sanofi-aventis U.S. LLC119$139,322
Mannkind Corporation96$100,534
Senseonics, Incorporated33$91,060
Eli Lilly4$84,438
AstraZeneca(2 entities)59$64,092
Sanofi US Services Inc.12$39,434
Ascensia Diabetes Care US Inc.53$21,753
Abbott48$19,581
Pfizer11$13,164
Tandem Diabetes Care, Inc.44$8,453
Sanofi1$8,320
Lilly USA, LLC143$3,434
Insulet Corporation51$2,791
Novo Nordisk164$2,593
Companion Medical, Inc.2$2,516
AbbVie129$1,397
Xeris Pharmaceuticals, Inc.63$1,045
Corcept Therapeutics42$807
Boehringer Ingelheim46$723
Bayer40$625
Amgen(2 entities)33$541
IBSA Pharma Inc.19$467
Merck24$332
Dexcom, Inc.17$266
Sequel Med Tech, LLC10$204
Antares Pharma, Inc.8$173
Smith+Nephew1$115
Johnson & Johnson8$107
Bigfoot Biomedical Inc4$85
Ascendis Pharma Endocrinology Inc4$79
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$76
Amneal Pharmaceuticals LLC5$71
Renalytix AI, Inc.1$52
Acella Pharmaceuticals, LLC3$48
Cequr Corporation2$43
Amphastar Pharmaceuticals, Inc.2$40
Shire North American Group Inc3$40
Organogenesis Inc.1$40
RGH Enterprises LLC2$39
Averitas Pharma Inc.2$39
Azurity Pharmaceuticals, Inc.2$36
Globus Medical1$33
Nalpropion Pharmaceuticals LLC2$28
Nevro Corp.2$28
Currax Pharmaceuticals LLC2$27
GRT US Holding, Inc.1$22
Madrigal Pharmaceuticals1$20
Echosens North America, Inc.1$16
Recordati_rare_diseases_inc.1$16
Amarin Pharma, Inc.1$15
Radius Health, Inc.1$14
Novartis1$13
Kyowa Kirin, Inc.1$13
Takeda Pharmaceuticals U.S.A., Inc.1$11
Clarus Therapeutics Inc.1$6
Travere Therapeutics, Inc.1$3

How this compares

Too few endocrinology providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$849,919
Medicare patients
1,253
Services billed
33,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology in Bartlett

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →